Entity

Time filter

Source Type

Elche de la Sierra, Spain

Farre Bernado N.,Servicio de Oncologia Radioterapica | Estorch Cabrera M.,Hospital de la Santa Creu i Sant Pau
DOLOR | Year: 2014

Bone metastases are the most common cause of cancer-related pain. The role of radiotherapy (RT) for palliation of painful bone metastases has been well established and achieves rates of pain relief in over 75[%] of patients. In the latest systematic reviews, there were no significant differences in complete and overall pain relief between single fraction (SF) and multiple fractions (MF), even though re-treatment rates were higher in patients treated with SF. Current radiotherapy techniques allow the administration of more accurate and less toxic treatments. Source


Vallejo Ocana C.,Servicio de Oncologia Radioterapica | Garrido Lopez P.,Servicio de Oncologia Medica | Muguruza T.Rueba. I.,Servicio de Cirugia Toracica
Clinical and Translational Oncology | Year: 2011

Lung cancer is the most frequent cause of cancer death worldwide and its global incidence has been steadily increasing during recent decades. A third of patients with newly diagnosed non-small-cell lung cancer (NSCLC) present with locally advanced disease. There is not a single widely accepted standard of care for these patients because of the wide spectrum of presentation of the disease. Although feasible and safe in experienced hands, evidence that surgical resection after induction treatment improves overall survival (OS) is lacking. For resectable or potentially resectable stage III, the fi ndings of two phase III trials suggest that surgical resection should not be considered a standard of care but rather reserved for selected patients after critical multidisciplinary assessment, in whom surgery improves survival after downstaging if pneumonectomy can be avoided or in some T4N0-1 resectable tumours. For unresectable stage III NSCLC the standard of care is a combination of chemotherapy and radiotherapy. In those patients with good performance status and minimal weight loss, the concurrent approach has resulted in a statistically signifi cant improvement in OS rates compared with a sequential approach in randomised clinical trials, although several questions remain unresolved. Source


Perez Romasanta L.A.,Servicio de Oncologia Radioterapica
Revisiones en Cancer | Year: 2011

The local therapy of Soft Tissue Sarcomas has evolved from amputation to conservative functional resections associated to radiotherapy in the last decades. The evolution has been made possible by randomized trials that demonstrated the superiority of this more conservative, combined-modality approach. Progressively, attention has moved to defining subsets of patients who might be adequately treated by surgery alone and defining the optimal sequence of surgery and radiation, preoperative or postoperative, for patients who require both types of local therapy. Regarding technological advances, it is worth to mention the introduction of Intensity Modulated Radiation Therapy (IMRT) in most cancer center's therapeutic arsenal, allowing for a high conformality and consequently a reduction of treatment morbidity. The brachytherapy and intraoperative radiotherapy have been used to treat the microscopic residual disease in the tumor bed. There is growing interest in the use of advanced treatment techniques associated to systemic therapy in the treatment of iresectable or high risk tumors. Finally, the Stereotactic Body Radiation Therapy (SBRT) is beginning to offer new expectations to the metastatic patients through a non-invasive treatment approach. Copyright © 2011 Aran Ediciones, S. L. Source


Approximately 60% of patients with a cancer diagnosis require radiotherapy. Although usually well tolerated, this treatment can sometimes produce radiation-related moderate-to-severe pain in certain locations or during painful procedures required for radiotherapy administration. This article describes two clinical situations of breakthrough pain in routine practice in radiotherapy departments: firstly, pain secondary to mucositis, which leads to weight loss and impaired quality of life; secondly, incidental pain caused by positioning and the maneuvers required for treatment administration. In both situations, we designed two prospective studies of fentanyl pectin nasal spray in the Fundación Jiménez Días. The results were satisfactory for both patients and healthcare professionals. These two studies remain open and are recruiting patients to confirm these results. © 2015 Sociedad Española de Cuidados Paliativos. Published by Elsevier España, S.L.U. All rights reserved. Source


Berral A.V.,Servicio de Oncologia Medica | Murua C.M.,Area de Cirugia | de la Vega F.A.,Servicio de Oncologia Radioterapica | Garcia I.H.,Servicio de Oncologia Medica | And 3 more authors.
Revista Espanola de Enfermedades Digestivas | Year: 2012

Gastric cancer is a disease with high incidence and mortality in our population. The prognosis of patients with this disease is closely related to the neoplasm stage at diagnosis, including the following characteristics of the tumor: extension into the gastric wall thickness, spread to locoregional lymph nodes and the ability to generate distant metastases, as described by the TNM classification. For localized tumors characterized only by invasion of mucosa or submucosa at diagnosis, survival at 5 years is between 70 and 95% with exclusive surgical management; however, when extension into the gastric wall is higher and/or there is locoregional nodal involvement, survival decreases to 20-30% at 5 years. Currently, at high-volume centers, the extent of gastrectomy is individualized based on several parameters, which in an increasing number of cases allows a total gastrectomy with D2 lymphadenectomy and preservation of the spleen and pancreas. This improved procedure increases the chance of R0 surgery and improves the relationship between resected and affected lymph nodes, resulting in a decreased risk of the long- term locoregional recurrence. To improve these results, different therapeutic strategies combining chemotherapy or chemoradiotherapy with surgery have been tested. Previously, the Intergroup 0116 clinical trial, published in 2001, which changed clinical practice in the United States, showed that adjuvant chemoradiotherapy improved survival (from 26 to 37 months overall survival) of these patients. In Europe, perioperative chemotherapy has been considered the standard treatment, since the publication of two randomized phase III trials showed an increase at 5 years survival in the group treated with chemotherapy. © 2012 Arán Ediciones, S. L. Source

Discover hidden collaborations